Ketamine Hydrochloride Inresa (Ketamine Hydrochloride)

Ketamine Hydrochloride is used in anesthesia and pain management by acting as an NMDA receptor antagonist.

• General anesthesia: induces a reversible dissociative state allowing surgical procedures without patient awareness.
• Procedural sedation: provides deep sedation for diagnostic or minor therapeutic procedures.
• Analgesia: offers potent pain relief for acute severe pain when other agents are insufficient.

• Ketamine Hydrochloride produces its effects primarily by non‑competitive antagonism of the N‑methyl‑D‑aspartate (NMDA) receptor in the central nervous system. By blocking excitatory glutamate transmission, it reduces neuronal firing and disrupts pain pathways, leading to dissociative anesthesia and analgesia. Additional actions at opioid receptors, monoaminergic pathways, and voltage‑gated calcium channels contribute to its cardiovascular stability and psychomimetic profile.

Ketamine Hydrochloride may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Hypertension or tachycardia: transient increase in blood pressure and heart rate.
• Nausea or vomiting: gastrointestinal discomfort during or after administration.
• Dissociation or vivid dreams: sense of detachment from environment.
• Salivation or airway secretions: increased oral secretions.
• Dizziness or headache: mild neurologic symptoms.

Serious or Rare Side Effects

• Respiratory depression: severe reduction in breathing requiring support.
• Psychotomimetic reactions: emergence phenomena such as hallucinations or agitation.
• Cardiac arrhythmias: irregular heart rhythms in susceptible patients.
• Allergic reactions: anaphylaxis or severe skin rash.

When using Ketamine Hydrochloride, clinicians should observe specific precautions to minimize risks.

• Patient selection: avoid use in patients with uncontrolled hypertension or severe coronary disease.
• Psychiatric history: exercise caution in individuals with schizophrenia or psychosis.
• Concurrent CNS depressants: monitor for additive respiratory effects.
• Pregnancy and lactation: weigh benefits against potential fetal or neonatal risks.
• Monitoring: continuously assess cardiovascular and respiratory status during administration.
• Store below 25°C: keep in original container, protect from light and moisture.

Ketamine Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Benzodiazepines: may blunt anesthetic effects and increase respiratory depression.
• Opioids: synergistic respiratory depression risk.
• Sympathomimetic agents: may exacerbate hypertension and tachycardia.

Moderate Interactions (Monitor Closely)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
• Anticholinergic drugs: may increase secretions and airway obstruction.
• CYP450 inhibitors/inducers: may affect ketamine metabolism, requiring dose adjustment.